Theratechnologies Announces Completion of NASDAQ Delisting

Theratechnologies Announces Completion of NASDAQ Delisting 
MONTREAL, CANADA -- (Marketwire) -- 02/05/13 -- Theratechnologies
Inc. (TSX:TH) announced today that the delisting of its common shares
on the NASDAQ Global Market (NASDAQ) is completed. Theratechnologies'
common shares continue trading on the Toronto Stock Exchange (TSX)
under the trading symbol "TH". 
On January 14, 2013, we announced our intent to voluntarily delist
our common shares from the NASDAQ and a Form 25 was subsequently
filed on January 28, 2013, with the Securities and Exchange
Commission (SEC). Notwithstanding the delisting of our common shares
from the NASDAQ, we will continue filing our periodic documents as a
foreign private issuer with the SEC pursuant to Sections 15(d) of the
Securities Exchange Act of 1934, as amended, (Exchange Act) for at
least 12 months until we can demonstrate that our shareholdings is
comprised of less than 300 persons resident in the United States or
that the average daily trading volume of our common shares in the
United States over that 12-month period is no greater than five
percent of the average daily trading volume of our common shares on a
worldwide basis. 
About Theratechnologies  
Theratechnologies (TSX:TH) is a biopharmaceutical company that
specializes in innovative therapeutic peptide products, with an
emphasis on growth-hormone releasing factor peptides. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on the
SEC's website at www.sec.gov.  
Forward-Looking Information  
This press release contains certain statements that are considered
"forward-looking information" within the meaning of applicable
securities legislation, which statements may contain such words as
"may", "would", "could", "will", "intend", "plan", "anticipate",
"believe", "estimate", "expect" and similar expressions. This
forward-looking information includes, but is not limited to,
information regarding the continuous trading of our common shares on
the TSX, our continuous reporting with the SEC and our capacity to
cease our reporting with the SEC. 
Forward-looking information is based upon a number of assumptions and
is subject to a number of risks and uncertainties, many of which are
beyond Theratechnologies' control that could cause actual results to
differ materially from those that are disclosed in or implied by such
forward-looking information. These assumptions include, but are not
limited to, the fact that we will remain in good standing with
securities laws applicable to us and the rules and regulation of the
TSX, that no cease trading order will be issued against us, that we
incur no financial difficulty leading us to seek exemptions from our
reporting obligations and that we can meet the requirements described
under Rule 12h-6(a)(4) of the Exchange Act to cease reporting with
the SEC. These risks and uncertainties include, but are not limited
to, the risk that we are unable to comply with securities laws and
the rules and regulations of the TSX, that a cease trading order is
issued against us and that we cannot meet the requirements described
under Rule 12h-6(a)(4) of the Exchange Act to cease reporting with
the SEC.  
Theratechnologies refers potential investors to the "Risk Factors"
section of its Annual Information Form (AIF) dated February 27, 2012.
The AIF is available at www.sedar.com and at www.sec.gov under
Theratechnologies' public filings. The reader is cautioned to
consider these and other risks and uncertainties carefully and not to
put undue reliance on forward-looking statements. Forward-looking
information reflects current expectations regarding future events and
speaks only as of the date of this press release and represents
Theratechnologies' expectations as of that date. 
Theratechnologies undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise, except
as may be required by applicable law.
Contacts:
Denis Boucher
NATIONAL Public Relations
514-843-2393
 
 
Press spacebar to pause and continue. Press esc to stop.